Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68,657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Kwak JY, et al. Among authors: park js, park j. Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939746 Clinical Trial.
Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.
Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Kim SJ, et al. Among authors: park js, park sk, park cw. Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29. Acta Haematol. 2009. PMID: 19887776
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Sohn SK, et al. Among authors: park js, park ek, park sy, park mr, park j. Leuk Lymphoma. 2011 Jun;52(6):1024-9. doi: 10.3109/10428194.2011.563885. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463107 Clinical Trial.
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).
Kim YR, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, Oh SY, Lee S, Park EK, Jang JS, Lee WS, Lee HW, Eom H, Ahn JS, Jeong JH, Baek SK, Kim SJ, Kim WS, Suh C. Kim YR, et al. J Hematol Oncol. 2012 Aug 13;5:49. doi: 10.1186/1756-8722-5-49. J Hematol Oncol. 2012. PMID: 22889180 Free PMC article.
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW. Lee SE, et al. Among authors: park je, park js. Am J Hematol. 2013 Jun;88(6):449-54. doi: 10.1002/ajh.23427. Epub 2013 Mar 28. Am J Hematol. 2013. PMID: 23440689 Free article.
Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.
Kim JS, Cheong JW, Shin HJ, Lee JW, Lee JH, Yang DH, Lee WS, Kim H, Park JS, Kim SH, Kim YS, Kwak JY, Chae YS, Park J, Do YR, Min YH. Kim JS, et al. Among authors: park js, park j. Yonsei Med J. 2014 Jan;55(1):9-18. doi: 10.3349/ymj.2014.55.1.9. Yonsei Med J. 2014. PMID: 24339281 Free PMC article.
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Kim SH, et al. Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4. Haematologica. 2014. PMID: 24705186 Free PMC article. Clinical Trial.
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
Eom KS, Kim SJ, Lee JJ, Suh C, Kim JS, Yoon SS, Kim BS, Kang HJ, Choi YJ, Kim CS, Kim YS, Kwak JY, Kim YJ, Joo YD, Mun YC, Jo DY, Park JS, Park CY, Kim SH, Min CK. Eom KS, et al. Biomed Res Int. 2014;2014:245247. doi: 10.1155/2014/245247. Epub 2014 Jun 23. Biomed Res Int. 2014. PMID: 25050331 Free PMC article. Clinical Trial.
68,657 results
You have reached the last available page of results. Please see the User Guide for more information.